Pyxis Oncology announces mixed Phase 1 PYX-201 data, collaboration with Merck, and analyst downgrade citing limited efficacy ...

Pyxis Oncology (PYXS) announced preliminary data from the ongoing Phase 1 clinical dose escalation study evaluating PYX-201 in multiple types of solid tumors. PYX-201, the company’s lead ...

— PYX-201 achieved a confirmed 50% ORR by RECIST 1.1 including one Complete Response and 100% Disease Control Rate in six heavily pretreated HNSCC patients, supporting differentiated mono and ...

Pyxis Oncology (Nasdaq: PYXS) has announced what look like encouraging early data from a Phase I trial of PYX-201, its lead antibody-drug conjugate (ADC), in solid tumors. Investors took a different ...

- PYX-201 achieved a confirmed 50% ORR by RECIST 1.1 including one Complete Response and 100% Disease Control Rate in six heavily pretreated HNSCC patients, supporting differentiated mono and ...

— PYX-201 achieved a confirmed 50% ORR by RECIST 1.1 including one Complete Response and 100% Disease Control Rate in six heavily pretreated HNSCC patients, supporting differentiated mono and ...

December 2, 2024 • The focal point of the case is 2009 law enacted by Congress that gives the Food and Drug Administration a mandate to curb the availability of nicotine products for minors.

Shares of Pyxis Oncology plummeted 46% after Phase 1 results for PYX-201, prompting a downgrade by William Blair.